2 weeks Ago By Defense World Staff
Integra LifeSciences Holdings Co. ( NASDAQ:IART – Get Free Report ) has received an average recommendation of “Reduce” from the eight analysts that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company.
The average 12-month price objective among analysts that have covered the stock in the last year is $24.00. Several analysts have issued reports on IART shares.
Truist Financial dropped their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th.
BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Bank of America dropped their price objective on Integra LifeSciences from $26.00 to $18.
00 and set an “underperform” rating on the stock in a research note on Monday, October 7th. Citigroup lifted their target price on Integra LifeSciences from $16.00 to $22.
00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Finally, JMP Securities decreased their target price on Integra LifeSciences from $40.00 to $35.
00 and set a “market outperform” rating on the stock in a report on Tuesday, July 30th. Read Our Latest Analysis on IART Institutional Inflows and Outflows Integra LifeSciences Stock Performance Integra LifeSciences stock opened at $23.27 on Tuesday.
Integra LifeSciences has a 1 year low of $16.81 and a 1 year high of $45.42.
The company’s 50-day moving average is $19.46 and its two-hundred day moving average is $24.25.
The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.
79. The company has a market cap of $1.80 billion, a PE ratio of -258.
53, a PEG ratio of 0.84 and a beta of 1.08.
Integra LifeSciences ( NASDAQ:IART – Get Free Report ) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.
39 by $0.02. Integra LifeSciences had a negative net margin of 0.
42% and a positive return on equity of 12.35%. The business had revenue of $380.
80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same period last year, the company posted $0.
76 EPS. Integra LifeSciences’s revenue for the quarter was down .4% on a year-over-year basis.
Equities analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year. Integra LifeSciences Company Profile ( Get Free Report Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. Read More Five stocks we like better than Integra LifeSciences What is Insider Trading? What You Can Learn from Insider Trading 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick What Does Downgrade Mean in Investing? Mouse Rising: The Iger Investment Pays Off for Disney Investors Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
